Close to 80% of what influences how long someone is going to live is where and how they live, and we need to pay more attention to that or we’re not paying attention to everything that affects their lives, explained David A. Eagle, MD, of New York Cancer & Blood Specialists.
Close to 80% of what influences how long someone is going to live is where and how they live, and as community oncologists, we need to pay more attention to that or we’re not paying attention to everything that affects their lives, explained David A. Eagle, MD, of New York Cancer & Blood Specialists.
Transcript
What are some of today’s most pressing issues in community oncology?
Health equity is the current issue. A lot of the challenge for oncologists is, where do we put our attention. I’m glad we’re going to put it toward health equity. We spend a lot of time focusing on the medical care of our patients—which is incredibly important—but if you want to predict how long somebody is going to live, about 80% of that is where they live and how they live and not the medical care they receive. So we need to pay more attention to that. If we don’t pay attention to that, we’re not paying attention to everything that affects their lives.
I think one thing that we need to figure out in the oncology community is how to go from a reactive model to a proactive model. We need to figure out how to screen people at the very beginning of their health care journey about what their needs are, where the gaps are, and not wait until we hear about problems.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More